[18F]ABBV-964i
Progressive Supranuclear Palsy (PSP)
InvicroEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Progressive Supranuclear Palsy (PSP) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IOFLUPANE GE Healthcare | Phase 3 | BB |
Zoledronate California Pacific Medical Center Research Institute | Phase 4 | BB |
IOFLUPANE GE Healthcare | Phase 3 | BB |
Riluzole King's College London | Phase 3 | B |
[18F]MNI-958 Invicro | Phase 1 | B |
View all 26 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →